SCHEMBL2064656

SCHEMBL2064656

CC(C)(C)OC(=O)N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CC#N)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.47
RPS6KB1 P23443 10/20 0.47
AKT1 P31749 10/20 0.47
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
CNR1 P21554 2/20 0.45
GPR35 Q9HC97 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
TRPV3 Q8NET8 1/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
KMT2A Q03164 2/20 0.42
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11904557 0.89 RPS6KB1 (0.49) GPR119RPS6KB1AKT1
SCHEMBL2063679 0.89 RPS6KB1 (0.51) GPR119RPS6KB1AKT1MAPTNPSR1
SCHEMBL2063243 0.88 RPS6KB1 (0.49) RPS6KB1AKT1MAPTNPSR1CNR1
SCHEMBL11904260 0.88 RPS6KB1 (0.60) RPS6KB1AKT1
SCHEMBL2062977 0.87 RPS6KB1 (0.51) RPS6KB1AKT1
SCHEMBL2063633 0.86 RPS6KB1 (0.51) RPS6KB1AKT1MAPTNPSR1CNR1
SCHEMBL11904466 0.85 RPS6KB1 (0.52) GPR119RPS6KB1AKT1MAPTNPSR1
SCHEMBL2064139 0.84 RPS6KB1 (0.46) GPR119RPS6KB1AKT1MAPTNPSR1
SCHEMBL11904259 0.84 RPS6KB1 (0.47) RPS6KB1AKT1MAPTNPSR1CNR1
SCHEMBL11904320 0.83 RPS6KB1 (0.53) RPS6KB1AKT1MAPTNPSR1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216302-B Akt and p70 s6 kinase inhibitors LILLY CO ELI 2013-08-21 CN disclosed
EP-2358710-B1 AKT AND P70 S6 KINASE INHIBITORS LILLY CO ELI (US) 2012-08-15 EP disclosed
US-8148387-B2 AKT and P70 S6 kinase inhibitors ELI LILLY AND COMPANY (US) 2012-04-03 US disclosed
CN-102216302-A Akt and p70 s6 kinase inhibitors LILLY CO ELI 2011-10-12 CN disclosed
US-20100120801-A1 AKT AND P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120801-A1 AKT AND P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, MTOR GPR119 1116/4885RPS6KB1 7/4885AKT1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.